Treatment of recurrent herpes simplex labialis with oral acyclovir

Spotswood L. Spruance, Jeffery Stewart, Nathaniel H. Rowe, Mark B. McKeough, Gay Wenerstrom, Donna J. Freeman

Research output: Contribution to journalArticle

138 Citations (Scopus)

Abstract

In a double-blind, randomized, patient-initiated clinical trial, 174 nonimmunocompromised patients with a history of virus-culture-confirmed herpes simplex labialis were treated with acyclovir capsules, 400 mg five times daily for 5 days, or placebo capsules. For 97% of the patients, treatment started within 1 h of the first sign or symptom of a recurrence. The frequency of positive lesion virus cultures was significantly lower among acyclovir-treated subjects (29/114, 25%) than among placebo-treated subjects (29/60, 48%; P = .004). Drug treatment did not affect the development of lesions, measured by the frequency of macular and papular (aborted) lesions and mean maximum lesion size. However, acyclovir hastened lesion resolution among the pa-tients who could start treatment in the prodrome or erythema lesion stage. For this group, the mean duration of pain was reduced by 36% (P = .02) and the mean healing time to loss of crust by 27% (P = .03). Thus, oral acyclovir alleviated some of the clinical manifestations of herpes simplex labialis.

Original languageEnglish (US)
Pages (from-to)185-190
Number of pages6
JournalJournal of Infectious Diseases
Volume161
Issue number2
StatePublished - Feb 1990
Externally publishedYes

Fingerprint

Herpes Labialis
Herpes Simplex
Acyclovir
Capsules
Placebos
Viruses
Therapeutics
Erythema
Signs and Symptoms
Clinical Trials
Recurrence
Pain
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Spruance, S. L., Stewart, J., Rowe, N. H., McKeough, M. B., Wenerstrom, G., & Freeman, D. J. (1990). Treatment of recurrent herpes simplex labialis with oral acyclovir. Journal of Infectious Diseases, 161(2), 185-190.

Treatment of recurrent herpes simplex labialis with oral acyclovir. / Spruance, Spotswood L.; Stewart, Jeffery; Rowe, Nathaniel H.; McKeough, Mark B.; Wenerstrom, Gay; Freeman, Donna J.

In: Journal of Infectious Diseases, Vol. 161, No. 2, 02.1990, p. 185-190.

Research output: Contribution to journalArticle

Spruance, SL, Stewart, J, Rowe, NH, McKeough, MB, Wenerstrom, G & Freeman, DJ 1990, 'Treatment of recurrent herpes simplex labialis with oral acyclovir', Journal of Infectious Diseases, vol. 161, no. 2, pp. 185-190.
Spruance SL, Stewart J, Rowe NH, McKeough MB, Wenerstrom G, Freeman DJ. Treatment of recurrent herpes simplex labialis with oral acyclovir. Journal of Infectious Diseases. 1990 Feb;161(2):185-190.
Spruance, Spotswood L. ; Stewart, Jeffery ; Rowe, Nathaniel H. ; McKeough, Mark B. ; Wenerstrom, Gay ; Freeman, Donna J. / Treatment of recurrent herpes simplex labialis with oral acyclovir. In: Journal of Infectious Diseases. 1990 ; Vol. 161, No. 2. pp. 185-190.
@article{e1eb31b53b5549bc9b5a41dec5b2c708,
title = "Treatment of recurrent herpes simplex labialis with oral acyclovir",
abstract = "In a double-blind, randomized, patient-initiated clinical trial, 174 nonimmunocompromised patients with a history of virus-culture-confirmed herpes simplex labialis were treated with acyclovir capsules, 400 mg five times daily for 5 days, or placebo capsules. For 97{\%} of the patients, treatment started within 1 h of the first sign or symptom of a recurrence. The frequency of positive lesion virus cultures was significantly lower among acyclovir-treated subjects (29/114, 25{\%}) than among placebo-treated subjects (29/60, 48{\%}; P = .004). Drug treatment did not affect the development of lesions, measured by the frequency of macular and papular (aborted) lesions and mean maximum lesion size. However, acyclovir hastened lesion resolution among the pa-tients who could start treatment in the prodrome or erythema lesion stage. For this group, the mean duration of pain was reduced by 36{\%} (P = .02) and the mean healing time to loss of crust by 27{\%} (P = .03). Thus, oral acyclovir alleviated some of the clinical manifestations of herpes simplex labialis.",
author = "Spruance, {Spotswood L.} and Jeffery Stewart and Rowe, {Nathaniel H.} and McKeough, {Mark B.} and Gay Wenerstrom and Freeman, {Donna J.}",
year = "1990",
month = "2",
language = "English (US)",
volume = "161",
pages = "185--190",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Treatment of recurrent herpes simplex labialis with oral acyclovir

AU - Spruance, Spotswood L.

AU - Stewart, Jeffery

AU - Rowe, Nathaniel H.

AU - McKeough, Mark B.

AU - Wenerstrom, Gay

AU - Freeman, Donna J.

PY - 1990/2

Y1 - 1990/2

N2 - In a double-blind, randomized, patient-initiated clinical trial, 174 nonimmunocompromised patients with a history of virus-culture-confirmed herpes simplex labialis were treated with acyclovir capsules, 400 mg five times daily for 5 days, or placebo capsules. For 97% of the patients, treatment started within 1 h of the first sign or symptom of a recurrence. The frequency of positive lesion virus cultures was significantly lower among acyclovir-treated subjects (29/114, 25%) than among placebo-treated subjects (29/60, 48%; P = .004). Drug treatment did not affect the development of lesions, measured by the frequency of macular and papular (aborted) lesions and mean maximum lesion size. However, acyclovir hastened lesion resolution among the pa-tients who could start treatment in the prodrome or erythema lesion stage. For this group, the mean duration of pain was reduced by 36% (P = .02) and the mean healing time to loss of crust by 27% (P = .03). Thus, oral acyclovir alleviated some of the clinical manifestations of herpes simplex labialis.

AB - In a double-blind, randomized, patient-initiated clinical trial, 174 nonimmunocompromised patients with a history of virus-culture-confirmed herpes simplex labialis were treated with acyclovir capsules, 400 mg five times daily for 5 days, or placebo capsules. For 97% of the patients, treatment started within 1 h of the first sign or symptom of a recurrence. The frequency of positive lesion virus cultures was significantly lower among acyclovir-treated subjects (29/114, 25%) than among placebo-treated subjects (29/60, 48%; P = .004). Drug treatment did not affect the development of lesions, measured by the frequency of macular and papular (aborted) lesions and mean maximum lesion size. However, acyclovir hastened lesion resolution among the pa-tients who could start treatment in the prodrome or erythema lesion stage. For this group, the mean duration of pain was reduced by 36% (P = .02) and the mean healing time to loss of crust by 27% (P = .03). Thus, oral acyclovir alleviated some of the clinical manifestations of herpes simplex labialis.

UR - http://www.scopus.com/inward/record.url?scp=0025159265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025159265&partnerID=8YFLogxK

M3 - Article

C2 - 2153735

AN - SCOPUS:0025159265

VL - 161

SP - 185

EP - 190

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -